BR112020007731A2 - composição farmacêutica para o tratamento de linfoma de células b, uso do obinutuzumabe e método para tratar o linfoma de células b cd20-positivo - Google Patents

composição farmacêutica para o tratamento de linfoma de células b, uso do obinutuzumabe e método para tratar o linfoma de células b cd20-positivo Download PDF

Info

Publication number
BR112020007731A2
BR112020007731A2 BR112020007731-3A BR112020007731A BR112020007731A2 BR 112020007731 A2 BR112020007731 A2 BR 112020007731A2 BR 112020007731 A BR112020007731 A BR 112020007731A BR 112020007731 A2 BR112020007731 A2 BR 112020007731A2
Authority
BR
Brazil
Prior art keywords
obinutuzumab
administration
cycle
hour
pharmaceutical composition
Prior art date
Application number
BR112020007731-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Michael Wenger
Mehrdad MOBASHER
Chin-Yu Lin
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020007731(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of BR112020007731A2 publication Critical patent/BR112020007731A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
BR112020007731-3A 2017-10-19 2018-10-19 composição farmacêutica para o tratamento de linfoma de células b, uso do obinutuzumabe e método para tratar o linfoma de células b cd20-positivo BR112020007731A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
US62/574,297 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 PHARMACEUTICAL COMPOSITION

Publications (1)

Publication Number Publication Date
BR112020007731A2 true BR112020007731A2 (pt) 2020-10-20

Family

ID=64362606

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020007731-3A BR112020007731A2 (pt) 2017-10-19 2018-10-19 composição farmacêutica para o tratamento de linfoma de células b, uso do obinutuzumabe e método para tratar o linfoma de células b cd20-positivo

Country Status (14)

Country Link
US (2) US12129304B2 (cg-RX-API-DMAC10.html)
EP (2) EP3697818B1 (cg-RX-API-DMAC10.html)
JP (2) JP6860652B2 (cg-RX-API-DMAC10.html)
KR (3) KR20260011191A (cg-RX-API-DMAC10.html)
CN (2) CN111212854A (cg-RX-API-DMAC10.html)
AU (2) AU2018303836B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020007731A2 (cg-RX-API-DMAC10.html)
CA (1) CA3079374A1 (cg-RX-API-DMAC10.html)
ES (1) ES3005784T3 (cg-RX-API-DMAC10.html)
IL (2) IL273909B2 (cg-RX-API-DMAC10.html)
MX (2) MX419643B (cg-RX-API-DMAC10.html)
PL (1) PL3697818T3 (cg-RX-API-DMAC10.html)
TW (2) TWI828593B (cg-RX-API-DMAC10.html)
WO (1) WO2019017499A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3697818T3 (pl) * 2017-10-19 2025-03-24 F. Hoffmann-La Roche Ag Leczenie CD20-dodatniego chłoniaka z limfocytów B obinutuzumabem
AU2020356896B2 (en) * 2019-10-04 2026-07-30 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant CD20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type II anti-CD20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
WO2023042679A1 (ja) 2021-09-17 2023-03-23 キヤノン株式会社 送電装置および受電装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
WO2009080541A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Antibody formulation
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US12377681B2 (en) 2017-07-21 2025-08-05 The Yokohama Rubber Co., Ltd. Pneumatic tire
PL3697818T3 (pl) * 2017-10-19 2025-03-24 F. Hoffmann-La Roche Ag Leczenie CD20-dodatniego chłoniaka z limfocytów B obinutuzumabem

Also Published As

Publication number Publication date
WO2019017499A2 (en) 2019-01-24
MX2020003418A (es) 2020-07-20
CN120983618A (zh) 2025-11-21
TWI828593B (zh) 2024-01-01
TW202342099A (zh) 2023-11-01
JP2019528282A (ja) 2019-10-10
JP6860652B2 (ja) 2021-04-21
IL321935A (en) 2025-09-01
KR20200067196A (ko) 2020-06-11
TW201922284A (zh) 2019-06-16
JP2021152002A (ja) 2021-09-30
EP3697818B1 (en) 2024-11-27
CA3079374A1 (en) 2019-01-24
KR20240157135A (ko) 2024-10-31
IL273909B1 (en) 2025-08-01
IL273909A (en) 2020-05-31
WO2019017499A3 (en) 2019-02-21
EP4520347A3 (en) 2025-06-04
EP4520347A2 (en) 2025-03-12
US20250026847A1 (en) 2025-01-23
MX419643B (es) 2025-01-14
KR20260011191A (ko) 2026-01-22
IL273909B2 (en) 2025-12-01
US12129304B2 (en) 2024-10-29
MX2024009217A (es) 2024-11-08
KR102766089B1 (ko) 2025-02-13
JP7370357B2 (ja) 2023-10-27
TWI805630B (zh) 2023-06-21
AU2025205481A1 (en) 2025-08-07
KR102906969B1 (ko) 2026-01-05
PL3697818T3 (pl) 2025-03-24
AU2018303836B2 (en) 2025-04-17
US20200299398A1 (en) 2020-09-24
ES3005784T3 (en) 2025-03-17
CN111212854A (zh) 2020-05-29
AU2018303836A1 (en) 2020-05-14
EP3697818A2 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
BR112019015426A2 (pt) Composição farmacêutica para uso no tratamento ou prevenção de uma doença relacionada a c5 e um método para tratar ou prevenir uma doença rela-cionada a c5
US20250026847A1 (en) Treatment of cd20-positive b-cell lymphoma with obinutuzumab
BR112021010789A2 (pt) Anticorpos anti-il-36r para o tratamento de pustulose palmoplantar
TWI865644B (zh) 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
WO2019072220A1 (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
TW202606756A (zh) 用於皮下投予之抗cd38抗體的調配物
CA3181827A1 (en) Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint
EP4100030A1 (en) Oncolytic virus compositions and methods for the treatment of cancer
BR122025025322A2 (pt) Composição farmacêutica para o tratamento de linfoma de células b e uso do obinutuzumabe
KR20220121793A (ko) 이식편대숙주 질환의 예방 또는 치료에 있어서의 화합물의 용도
HK40031517A (en) Treatment of cd20-positive b-cell lymphoma with obituzumab
WO2019011918A1 (en) TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
WO2016189491A1 (en) Novel formulation
BR102022017167A2 (pt) Terapia anti-cd19 em combinação com lenalidomida para o tratamento de leucemia ou linfoma
WO2026101890A1 (en) Combinations of anti-il-27 antibodies with toripalimab and bevacizumab
BR112023008592B1 (pt) USO DE (I) UM AGENTE ANTIVIRAL PARA A HEPATITE B E (II) UMA COMPOSIÇÃO DE VACINA QUE INCLUI UM ANTÍGENO, UM LIPOPEPTÍDEO E UM ADJUVANTE POLI(l:C) DESTINADO À FABRICAÇÃO DE UM MEDICAMENTO PARA PREVENIR OU TRATAR HEPATITE B CRÓNICA POR COADMINISTRAÇÃO DE (I) E (II), E KIT DE FORMULAÇÃO COMBINADA QUE COMPREENDE (I) E (II)
CN118871129A (zh) 抗tim-3抗体与去甲基化药物的药物组合
JP2022546686A (ja) 形質細胞に対する抑制剤または細胞傷害剤を使用する慢性疲労症候群の処置のための方法

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025025322-7 PROTOCOLO 870250105568 EM 18/11/2025 16:01.